maprotiline has been researched along with sertraline in 16 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (6.25) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 6 (37.50) | 29.6817 |
2010's | 8 (50.00) | 24.3611 |
2020's | 1 (6.25) | 2.80 |
Authors | Studies |
---|---|
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
Bleich, S; Gulbins, E; Kornhuber, J; Reichel, M; Terfloth, L; Tripal, P; Wiltfang, J | 1 |
Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
Glen, RC; Lowe, R; Mitchell, JB | 1 |
Gozalbes, R; Pineda-Lucena, A | 1 |
Ekins, S; Williams, AJ; Xu, JJ | 1 |
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
Fijorek, K; Glinka, A; Mendyk, A; Polak, S; Wiśniowska, B | 1 |
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Lautin, A; Novatt, A; Peselow, ED; Rohrs, C; Rotrosen, J; Siekierski, J; Wolkin, A | 1 |
Harvey, AT; Preskorn, SH; Rudolph, RL | 1 |
Jacob, C; Luckhaus, C | 1 |
Koval'chuk, VV | 1 |
Yamini, Y; Zamani, R | 1 |
1 review(s) available for maprotiline and sertraline
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 trial(s) available for maprotiline and sertraline
Article | Year |
---|---|
The dexamethasone suppression test and response to placebo.
Topics: 1-Naphthylamine; Clinical Trials as Topic; Depressive Disorder; Dexamethasone; Double-Blind Method; Humans; Maprotiline; Placebos; Sertraline | 1986 |
[Pharmacologic correction of psycho-emotive disorders in the rehabilitation of patients after removal of brain tumors].
Topics: Adult; Alprazolam; Amitriptyline; Anti-Anxiety Agents; Antidepressive Agents; Anxiety; Brain Neoplasms; Depression; Doxepin; Emotions; Female; Humans; Male; Maprotiline; Middle Aged; Moclobemide; Mood Disorders; Neurosurgical Procedures; Nialamide; Sertraline; Thiazepines; Trazodone; Treatment Outcome | 2007 |
13 other study(ies) available for maprotiline and sertraline
Article | Year |
---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
Topics: Algorithms; Animals; Cell Line; Cell Line, Tumor; Chemical Phenomena; Chemistry, Physical; Enzyme Inhibitors; Humans; Hydrogen-Ion Concentration; Molecular Conformation; Quantitative Structure-Activity Relationship; Rats; Sphingomyelin Phosphodiesterase | 2008 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
Predicting phospholipidosis using machine learning.
Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine | 2010 |
QSAR-based solubility model for drug-like compounds.
Topics: Databases, Factual; Models, Molecular; Pharmaceutical Preparations; Quantitative Structure-Activity Relationship; Solubility; Water | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
Topics: Artificial Intelligence; Calcium Channel Blockers; Calcium Channels, L-Type; Cell Line; Computational Biology; Computer Simulation; Drugs, Investigational; Ether-A-Go-Go Potassium Channels; Expert Systems; Heart Rate; Humans; Models, Biological; Myocytes, Cardiac; NAV1.5 Voltage-Gated Sodium Channel; Potassium Channel Blockers; Quantitative Structure-Activity Relationship; Risk Assessment; Shaker Superfamily of Potassium Channels; Torsades de Pointes; Voltage-Gated Sodium Channel Blockers | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Evidence of the dual mechanisms of action of venlafaxine.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Antidepressive Agents, Second-Generation; Biological Transport, Active; Blood Platelets; Blood Pressure; Cyclohexanols; Dose-Response Relationship, Drug; Electrocardiography; Heart Rate; Humans; Injections, Intravenous; Male; Maprotiline; Middle Aged; Norepinephrine; Selective Serotonin Reuptake Inhibitors; Serotonin; Sertraline; Systole; Tyramine; Venlafaxine Hydrochloride | 2000 |
Venlafaxine withdrawal syndrome not prevented by maprotiline, but resolved by sertraline.
Topics: Aged; Antidepressive Agents, Second-Generation; Cyclohexanols; Female; Humans; Maprotiline; Nausea; Selective Serotonin Reuptake Inhibitors; Sertraline; Sleep Initiation and Maintenance Disorders; Substance Withdrawal Syndrome; Venlafaxine Hydrochloride | 2001 |
On-Chip Electromembrane Surrounded Solid Phase Microextraction for Determination of Tricyclic Antidepressants from Biological Fluids Using Poly(3,4-ethylenedioxythiophene)-Graphene Oxide Nanocomposite as a Fiber Coating.
Topics: Amitriptyline; Antidepressive Agents, Tricyclic; Desipramine; Humans; Imipramine; Limit of Detection; Maprotiline; Nanocomposites; Nortriptyline; Reproducibility of Results; Sertraline; Solid Phase Microextraction | 2023 |